MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
7.79
-0.21
-2.63%
Opening 15:17 09/22 EDT
OPEN
8.00
PREV CLOSE
8.00
HIGH
8.12
LOW
7.74
VOLUME
709.78K
TURNOVER
0
52 WEEK HIGH
14.93
52 WEEK LOW
6.33
MARKET CAP
635.92M
P/E (TTM)
-2.6233
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EDIT last week (0911-0915)?
Weekly Report · 4d ago
Weekly Report: what happened at EDIT last week (0904-0908)?
Weekly Report · 09/11 09:12
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?
NASDAQ · 09/08 09:03
Weekly Report: what happened at EDIT last week (0828-0901)?
Weekly Report · 09/04 10:39
Cantor Fitzgerald Keeps Their Buy Rating on Editas Medicine (EDIT)
TipRanks · 08/30 06:05
Cantor Fitzgerald Reiterates Editas Medicine (EDIT) Overweight Recommendation
NASDAQ · 08/30 00:46
Analyst Expectations for Editas Medicine's Future
Benzinga · 08/29 16:00
Cantor Fitzgerald Reiterates Overweight on Editas Medicine, Maintains $14 Price Target
Benzinga · 08/29 15:40
More
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.